How does 1558's PE Ratio compare to its peers?

1558 is good value based on its Price-To-Earnings Ratio (4.8x) compared to the peer average (8.1x).

How does 1558's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

1558 is good value based on its Price-To-Earnings Ratio (4.8x) compared to the Hong Kong Pharmaceuticals industry average (8.5x).

What is 1558's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 1558's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of 1558 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

1558 (HK$9.58) is trading below our estimate of [[fair value]] (HK$18.39)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

1558 Stock Overview

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. More details

1558 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 47.9% below our estimate of its fair value

Earnings grew by 44.7% over the past year

Risk Analysis

Earnings have declined by 2.1% per year over past 5 years

High level of non-cash earnings

My Notes

Capture your thoughts, links and company narrative

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Competitors

China Shineway Pharmaceutical Group

SEHK:2877

HK$7.5b

Shandong Xinhua Pharmaceutical

SEHK:719

HK$9.8b

Luye Pharma Group

SEHK:2186

HK$8.1b

SSY Group

SEHK:2005

HK$10.6b

Price History & Performance

Summary of share price highs, lows and changes for YiChang HEC ChangJiang Pharmaceutical
Historical stock prices
Current Share Price	HK$9.58
52 Week High	HK$10.56
52 Week Low	HK$7.92
Beta	0.079
1 Month Change	4.24%
3 Month Change	6.21%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-69.73%

Recent updates

Shareholder Returns

	1558	HK Pharmaceuticals	HK Market
7D	-2.3%	0.2%	1.5%
1Y	n/a	-3.7%	20.6%

Return vs Industry: Insufficient data to determine how 1558 performed against the Hong Kong Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 1558 performed against the Hong Kong Market.

Price Volatility

Is 1558's price volatile compared to industry and market?
1558 volatility
1558 Average Weekly Movement	5.8%
Pharmaceuticals Industry Average Movement	6.4%
Market Average Movement	8.8%
10% most volatile stocks in HK Market	18.6%
10% least volatile stocks in HK Market	4.0%

Stable Share Price: 1558 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: Insufficient data to determine 1558's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	4,891	Juncai Jiang	www.hec-changjiang.com

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, sells, and markets pharmaceutical products in the therapeutic areas of anti-infection, endocrine and metabolic, and other diseases in the People’s Republic of China. It manufactures and sells active pharmaceutical ingredients; researches and develops pharmaceutical products, and medical devices and drugs, as well as biotechnology; and provides marketing and medical consulting services.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Fundamentals Summary

How do YiChang HEC ChangJiang Pharmaceutical's earnings and revenue compare to its market cap?
1558 fundamental statistics
Market cap	HK$8.43b
Earnings (TTM)	HK$1.75b
Revenue (TTM)	HK$5.90b

4.8x

P/E Ratio

1.4x

P/S Ratio

Is 1558 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1558 income statement (TTM)
Revenue	CN¥5.54b
Cost of Revenue	CN¥1.17b
Gross Profit	CN¥4.37b
Other Expenses	CN¥2.72b
Earnings	CN¥1.65b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.87
Gross Margin	78.90%
Net Profit Margin	29.74%
Debt/Equity Ratio	23.9%

How did 1558 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 03:24
End of Day Share Price	2024/12/24 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ling Zhang	BNP Paribas Securities (Asia)
Ling Zhang	China Merchants Securities (HK) Co., Ltd
null null	CMB International Securities Limited

YiChang HEC ChangJiang Pharmaceutical SHSC:1558 Stock Report